Flex Pharma to Report First Quarter 2018 Financial Results on May 2, 2018
April 25 2018 - 3:19PM
Business Wire
Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology
company that is developing innovative and proprietary treatments
for cramps and spasticity associated with severe neurological
diseases such as multiple sclerosis (MS), Charcot-Marie-Tooth (CMT)
and amyotrophic lateral sclerosis (ALS) under FDA Fast Track
designation, announced today that it will report its financial
results for the first quarter ended March 31, 2018 on Wednesday,
May 2, 2018 before the U.S. financial markets open. The Company
will host a conference call and webcast at 9:00 a.m. ET to discuss
first quarter 2018 financial results and provide a business update.
Individuals interested in participating in the call should dial
(855) 780-7202 (U.S. and Canada) or (631) 485-4874
(International).
A live webcast may be accessed in the Investors & Media
section of the Company's website at www.flex-pharma.com. Please log
on to the Flex Pharma website approximately 15 minutes prior to the
scheduled webcast to ensure adequate time for any software
downloads that may be required. A replay of the webcast will be
available on Flex Pharma's website for 90 days following the
event.
About Flex Pharma
Flex Pharma, Inc. is a clinical-stage biotechnology company that
is developing innovative and proprietary treatments in Phase 2
randomized, controlled trials for cramps and spasticity associated
with the severe neurological diseases of ALS, MS and peripheral
neuropathies such as Charcot-Marie-Tooth (CMT). The Company’s lead
candidate, FLX-787, is being developed under Fast Track designation
for the treatment of severe muscle cramps associated with ALS. Flex
Pharma was founded by National Academy of Science members Rod
MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D.,
recognized leaders in the fields of ion channels and neurobiology,
along with Christoph Westphal, M.D., Ph.D.
Click to Tweet this News
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180425006590/en/
Flex Pharma, Inc.Elizabeth Woo, 617-874-1829SVP, Investor
Relations & Corporate Communicationsirdept@flex-pharma.com
FLEX PHARMA, INC. (NASDAQ:FLKS)
Historical Stock Chart
From May 2024 to Jun 2024
FLEX PHARMA, INC. (NASDAQ:FLKS)
Historical Stock Chart
From Jun 2023 to Jun 2024